Conatumumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFRSF10B/CD262, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.